A
ACET icon

Abingworth’s Adicet Bio ACET Stock Holding History

Abingworth’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$18.9M Hold
132,212
– – 6.16% 5
2022
Q3 		$30M Hold
132,212
– – 10.26% 4
2022
Q2 		$30.9M Hold
132,212
– – 9.89% 4
2022
Q1 		$42.2M Hold
132,212
– – 11.96% 3
2021
Q4 		$36.9M Buy
132,212
+31,250
+31% +$5.36M 8.94% 5
2021
Q3 		$12.6M Hold
100,962
– – 2.87% 10
2021
Q2 		$16.6M Hold
100,962
– – 5.12% 8
2021
Q1 		$21M Buy
+100,962
New +$23.2M 7.24% 4

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Abingworth's ACET Position: Q4 2022 in Review

Abingworth held its Adicet Bio (ACET) position steady in Q4 2022 at 132,212 shares worth $18.9M. The position accounts for 6.16% of the portfolio, ranked #5.

Abingworth first reported a position in ACET in Q1 2021 and has held it in 8 quarters since. The position peaked at $42.2M in Q1 2022. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • Abingworth held 132,212 shares of Adicet Bio worth $18.9M as of Q4 2022.
  • Abingworth left its Adicet Bio share count unchanged in Q4 2022.
  • Adicet Bio made up 6.16% of Abingworth's portfolio in Q4 2022, its #5 holding.
  • Abingworth first reported a position in Adicet Bio in Q1 2021 and has held it in 8 quarters since.
  • Abingworth's Adicet Bio position peaked at $42.2M in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.